Terms: = Lung cancer AND MET, RCCP2, 4233, ENSG00000105976, P08581, HGFR, AUTS9 AND Treatment
2436 results:
1. The impact of decision tools during oncological consultation with lung cancer patients: A systematic review within the I3lung project.
Sebri V; Marzorati C; Dorangricchia P; Monzani D; Grasso R; Prelaj A; Provenzano L; Mazzeo L; Dumitrascu AD; Sonnek J; Szewczyk M; Watermann I; Trovò F; Dollis N; Sarris E; Garassino MC; Bestvina CM; Pedrocchi A; Ambrosini E; Kosta S; Felip E; Soleda M; Roca AA; Rodríguez-Morató J; Nuara A; Lourie Y; Fernandez-Pinto M; Aguaron A; Pravettoni G
Cancer Med; 2024 May; 13(9):e7159. PubMed ID: 38741546
[TBL] [Abstract] [Full Text] [Related]
2. A real-world pharmacovigilance study of amivantamab-related cardiovascular adverse events based on the FDA adverse event reporting system (FAERS) database.
Sun R; Ning Z; Qin H; Zhang W; Teng Y; Jin C; Liu J; Wang A
Sci Rep; 2024 Apr; 14(1):9552. PubMed ID: 38664423
[TBL] [Abstract] [Full Text] [Related]
3. Comprehensive genomic profiling of pulmonary spindle cell carcinoma using tissue and plasma samples: insights from a real-world cohort analysis.
Sun Y; Qin S; Wang S; Pang J; Ou Q; Liang W; Zhong H
J Pathol Clin Res; 2024 May; 10(3):e12375. PubMed ID: 38661052
[TBL] [Abstract] [Full Text] [Related]
4. Recording and classifying met receptor mutations in cancers.
Guérin C; Tulasne D
Elife; 2024 Apr; 13():. PubMed ID: 38652103
[TBL] [Abstract] [Full Text] [Related]
5. Survival analysis after stereotactic ablative radiotherapy for early stage non-small cell lung cancer: a single-institution cohort study.
Resova K; Knybel L; Parackova T; Rybar M; Cwiertka K; Cvek J
Radiat Oncol; 2024 Apr; 19(1):50. PubMed ID: 38637844
[TBL] [Abstract] [Full Text] [Related]
6. Mobocertinib in Patients with EGFR Exon 20 Insertion-Positive Non-Small Cell lung cancer (MOON): An International Real-World Safety and Efficacy Analysis.
Illini O; Saalfeld FC; Christopoulos P; Duruisseaux M; Vikström A; Peled N; Demedts I; Dudnik E; Eisert A; Hashemi SMS; Janzic U; Kian W; Mohorcic K; Mohammed S; Silvoniemi M; Rothschild SI; Schulz C; Wesseler C; Addeo A; Armster K; Itchins M; Ivanović M; Kauffmann-Guerrero D; Koivunen J; Kuon J; Pavlakis N; Piet B; Sebastian M; Velthaus-Rusik JL; Wannesson L; Wiesweg M; Wurm R; Albers-Leischner C; Aust DE; Janning M; Fabikan H; Herold S; Klimova A; Loges S; Sharapova Y; Schütz M; Weinlinger C; Valipour A; Overbeck TR; Griesinger F; Jakopovic M; Hochmair MJ; Wermke M
Int J Mol Sci; 2024 Apr; 25(7):. PubMed ID: 38612799
[TBL] [Abstract] [Full Text] [Related]
7. [Clinical characteristics and prognosis analysis of pulmonary sarcomatoid carcinoma].
Feng XY; Chen MJ; Xu Y; Zhong W; Liu XY; Gao XX; Zhao J; Wang MZ
Zhonghua Jie He He Hu Xi Za Zhi; 2024 Apr; 47(4):319-324. PubMed ID: 38599806
[No Abstract] [Full Text] [Related]
8. A scoping review of vasculitis as an immune-related adverse event from checkpoint inhibitor therapy of cancer: Unraveling the complexities at the intersection of immunology and vascular pathology.
Lee CM; Wang M; Rajkumar A; Calabrese C; Calabrese L
Semin Arthritis Rheum; 2024 Jun; 66():152440. PubMed ID: 38579593
[TBL] [Abstract] [Full Text] [Related]
9. Efficacy and safety of tepotinib in Asian patients with advanced NSCLC with met exon 14 skipping enrolled in VISION.
Kato T; Yang JC; Ahn MJ; Sakai H; Morise M; Chen YM; Han JY; Yang JJ; Zhao J; Hsia TC; Berghoff K; Bruns R; Vioix H; Lang S; Johne A; Le X; Paik PK
Br J Cancer; 2024 Jun; 130(10):1679-1686. PubMed ID: 38575731
[TBL] [Abstract] [Full Text] [Related]
10. Comparison between next-generation sequencing and multiplex polymerase chain reaction assays for nonsmall-cell lung cancer molecular diagnosis.
Murakami S; Shinada K; Otsutsumi Y; Komine F; Yuan Y; Nakamura J; Katakura S; Kondo T; Kato T; Yokose T; Saito H
Cancer Med; 2024 Apr; 13(7):e7162. PubMed ID: 38572952
[TBL] [Abstract] [Full Text] [Related]
11. Patterns and treatment outcomes of primary bone tumors in children treated at tertiary referral hospital, Ethiopia.
Lingerih T; Yeshiwas S; Mohamedsaid A; Arega G
BMC Cancer; 2024 Mar; 24(1):394. PubMed ID: 38549062
[TBL] [Abstract] [Full Text] [Related]
12. Mobocertinib: Mechanism of action, clinical, and translational science.
Hanley MJ; Camidge DR; Fram RJ; Gupta N
Clin Transl Sci; 2024 Mar; 17(3):e13766. PubMed ID: 38511563
[TBL] [Abstract] [Full Text] [Related]
13. From osimertinib to preemptive combinations.
Blagosklonny MV
Oncotarget; 2024 Mar; 15():232-237. PubMed ID: 38497774
[TBL] [Abstract] [Full Text] [Related]
14. Modelling the Effectiveness of Tepotinib in Comparison to Standard-of-Care treatments in Patients with Advanced Non-small Cell lung cancer (NSCLC) Harbouring metex14 Skipping in the UK.
Batteson R; Hook E; Wheat H; Hatswell AJ; Vioix H; McLean T; Alexopoulos ST; Baijal S; Paik PK
Target Oncol; 2024 Mar; 19(2):191-201. PubMed ID: 38492157
[TBL] [Abstract] [Full Text] [Related]
15. Multicenter evaluation of an automated, multiplex, RNA-based molecular assay for detection of ALK, ROS1, RET fusions and met exon 14 skipping in NSCLC.
Melchior L; Hirschmann A; Hofman P; Bontoux C; Concha A; Mrabet-Dahbi S; Vannuffel P; Watkin E; Putzová M; Scarpino S; Cayre A; Martin P; Stoehr R; Hartmann A
Virchows Arch; 2024 Apr; 484(4):677-686. PubMed ID: 38492039
[TBL] [Abstract] [Full Text] [Related]
16. Anlotinib Inhibits Cisplatin Resistance in Non-Small-Cell lung cancer Cells by Inhibiting MCL-1 Expression via met/STAT3/Akt Pathway.
Wang L; Xu L; Han S; Zhu X
Can Respir J; 2024; 2024():2632014. PubMed ID: 38468814
[TBL] [Abstract] [Full Text] [Related]
17. Emerging role of tumor suppressing microRNAs as therapeutics in managing non-small cell lung cancer.
Singh S; Saxena S; Sharma H; Paudel KR; Chakraborty A; MacLoughlin R; Oliver BG; Gupta G; Negi P; Singh SK; Dua K
Pathol Res Pract; 2024 Apr; 256():155222. PubMed ID: 38452582
[TBL] [Abstract] [Full Text] [Related]
18. Stereotactic Radiation Therapy in Early Non-Small Cell lung cancer and Interstitial lung Disease: A Nonrandomized Clinical Trial.
Palma DA; Bahig H; Hope A; Harrow S; Debenham BJ; Louie AV; Vu TTTT; Filion E; Bezjak A; Campeau MP; Duimering A; Giuliani ME; Laba JM; Lang P; Lok BH; Qu XM; Raman S; Rodrigues GB; Goodman CD; Gaede S; Morisset J; Warner A; Dhaliwal I; Ryerson CJ
JAMA Oncol; 2024 May; 10(5):575-582. PubMed ID: 38451491
[TBL] [Abstract] [Full Text] [Related]
19. UV1 telomerase vaccine with ipilimumab and nivolumab as second line treatment for pleural mesothelioma - A phase II randomised trial.
Haakensen VD; Öjlert ÅK; Thunold S; Farooqi S; Nowak AK; Chin WL; Grundberg O; Szejniuk WM; Cedres S; Sørensen JB; Dalen TS; Lund-Iversen M; Bjaanæs M; Helland Å
Eur J Cancer; 2024 May; 202():113973. PubMed ID: 38447379
[TBL] [Abstract] [Full Text] [Related]
20. Distinct fibroblast subpopulations associated with bone, brain or intrapulmonary metastasis in advanced non-small-cell lung cancer.
Xu K; Wang H; Zou YX; Zhang HH; Wang YN; Ren XR; Wang HQ; Xu YH; Li JJ; Tang H; He C; Wei S; Tian T; Li LL; Zhou H; Xu LJ; Fang JW; Guo C; Yang JX; Zhou YY; Zhang ZH; Pan YY
Clin Transl Med; 2024 Mar; 14(3):e1605. PubMed ID: 38445456
[TBL] [Abstract] [Full Text] [Related]
[Next]